Save up -80% on Pregabalin
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Lyrica
|$438.33||60 capsules/150 mg|
|Price with discount in nearest pharmacy. Price may vary.|
We offer free Pregabalin coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your Lyrica coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Pregabalin every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Pregabalin volume of distribution
|Act Pregabalin||Capsule||150 mg||Oral||Actavis Pharma Company|
|Lyrica||Capsule||50 mg/1||Oral||Unit Dose Services|
|Lyrica CR||Tablet, film coated, extended release||165 mg/1||Oral||Parke Davis Div Of Pfizer Inc|
|M-pregabalin||Capsule||150 mg||Oral||Mantra Pharma Inc|
|Pregabalin||Capsule||300 mg||Oral||Laboratoire Riva Inc|
|Pregabalin Capsules||Capsule||50 mg||Oral||Lupin Pharmaceuticals|
|Pregabalin Pfizer||Capsule||225 mg||Oral||Pfizer|
|Pregabalin-150||Capsule||150 mg||Oral||Sivem Pharmaceuticals Ulc|
|Sandoz Pregabalin||Capsule||50 mg||Oral||Sandoz Canada Incorporated|
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Pregabalin
Pregabalin is an anticonvulsant drug used for neuropathic pain, as an adjunct therapy for partial seizures, and in generalized anxiety disorder. It was designed as a more potent successor to gabapentin. Pregabalin is marketed by Pfizer under the trade name Lyrica. It is considered to have a dependence liability if misused, and is classified as a Schedule V drug in the U.S. (Wikipedia)
Pregabalin mechanism of action
Pregabalin binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin is unknown, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha2-delta subunit may be involved in pregabalin’s antinociceptive and antiseizure effects in animal models. In vitro, pregabalin reduces the calcium-dependent release of several neurotransmitters, possibly by modulation of calcium channel function. Studies also suggest that the descending noradrenergic and serotonergic pathways originating from the brainstem may be involved with the mechanism of pregabalin. Interestingly, although pregabalin is a structural derivative of inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA or benzodiazepine receptors. The sodium channels, opiate receptors, and cyclooxygenase enzymes are not involved with the mechanism of pregabalin. It is also inactive at serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake.
Dosage forms of Pregabalin
|Lyrica 100 mg capsule||$2.88||capsule|
|Lyrica 150 mg capsule||$2.88||capsule|
|Lyrica 50 mg capsule||$2.88||capsule|
|Lyrica 75 mg capsule||$2.88||capsule|
|Lyrica 200 mg capsule||$2.75||capsule|
|Lyrica 225 mg capsule||$2.75||capsule|
|Lyrica 25 mg capsule||$2.75||capsule|
|Lyrica 300 mg capsule||$2.75||capsule|
Ach-pregabalin, Auro-pregabalin, Dom-pregabalin, Gd-pregabalin, Ipg-pregabalin, Jamp-pregabalin, Lyrica, Mar-pregabalin, Mint-pregabalin, Myl-pregabalin, Pendo-pregabalin, PMS-pregabalin, Pregabalin Accord, Pregabalin Mylan, Pregabalin Mylan Pharma, Pregabalin Zentiva, Ran-pregabalin, Ratio-pregabalin, Riva-pregabalin, Teva-pregabalin, Torrent-pregabalin
Act Pregabalin, Lyrica, Lyrica CR, M-pregabalin, Pregabalin, Pregabalin Capsules, Pregabalin Pfizer, Pregabalin-150, Sandoz Pregabalin
AS Medication Solutions, Actavis Pharma Company, Alembic Pharmaceuticals Limited, Bryant ranch prepack, Cardinal Health, Directrx, Dispensing Solutions, H.J. Harkins Company, Laboratoire Riva, Lake Erie Medical&Surgical Supply, Lupin Pharmaceuticals, Mantra Pharma Inc, Parke Davis Div Of Pfizer, Pd Rx Pharmaceuticals, Pfizer, Physicians Total Care, Pro Doc Limitee, Ranbaxy Inc, Rebel Distributors, Remedy Repack, Sandoz Canada Incorporated, Sanis Health Inc, Sivem Pharmaceuticals Ulc, St. Marys Medical Park Pharmacy, Stat Rx USA, U.S. Pharmaceuticals, Unit Dose Services
Humans and other mammals
Indication of Pregabalin
Pregabalin is used for the management of neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, and postherpetic neuralgia. It is also used as adjunctive therapy for adult patients with partial onset seizures and management of fibromyalgia.
Toxicity of Pregabalin
Most common adverse reactions (5% and twice placebo) are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain and thinking abnormal (primarily difficulty with concentration/attention).
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Pregabalin on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Lyrica now!
What is Lyrica?During the studies, the efficacy of the drug for the treatment of diabetic neuropathy, postherpetic neuralgia, and lesion of the spinal cord was demonstrated. The efficacy of the drug in other types of neuropathic pain has not been studied.
Lyrica was studied in 10 controlled clinical trials up to 13 weeks with a dosing regimen twice a day and in studies up to 8 weeks with a dosage regimen three times a day. In general, the safety and efficacy profiles for dosing regimens twice and three times a day were similar.
In clinical trials up to 12 weeks in which the drug was used to treat neuropathic pain, the reduction of peripheral and central pain was observed after the first week and was maintained throughout the treatment period.
In controlled clinical trials on peripheral neuropathic pain, 35% of pregabalin patients and 18% of patients receiving placebo experienced an improvement of 50% in the pain score. Among patients who did not have drowsiness, this improvement was observed in 33% of patients treated with pregabalin and in 18% of patients in the placebo group. Among patients who had drowsiness, the proportion of patients responding to therapy was 48% in the pregabalin group and 16% in the placebo group.
In a controlled clinical study of central neuropathic pain in 22% of pregabalin patients and in 7% of patients receiving placebo, an improvement was noted for 50% of the pain score.